コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 red to a time point early after the bivalent booster immunization.
2 rden in the nares at 6 weeks after the final booster immunization.
3 cells for augmented IgG responses following booster immunization.
4 ugmented PS-specific IgG responses following booster immunization.
5 d) were taken before and 28 days after PCV13 booster immunization.
6 CD8(+) T cell anamnestic response following booster immunization.
7 tivector antibodies did not interfere with a booster immunization.
8 obulin diversity, and cannot be corrected by booster immunization.
9 for the improved survival that results from booster immunization.
10 mediate the enhanced protection conferred by booster immunization.
11 virulent wild-type Lm without the need for a booster immunization.
12 above that seen in colonized controls after booster immunization.
13 ated to immunizing dose, and was enhanced by booster immunization.
14 n (KLH) before subcutaneous immunization and booster immunization.
15 accharide (PS)-specific IgG titers following booster immunization.
16 week 18 (P < 0.001), i.e., 3 weeks after the booster immunization.
17 er, 2 of 5 animals were given an intradermal booster immunization.
18 system to mount a more potent response after booster immunization.
19 ines is critical for informing the timing of booster immunization.
20 y and make informed decisions about COVID-19 booster immunization.
21 lymph nodes for at least 12 weeks after the booster immunization.
22 ing antibodies were generated after a single booster immunization.
23 antibodies expected to dampen the effect of booster immunizations.
24 iming followed by recombinant fowl pox virus booster immunizations.
25 se appeared to be augmented following dermal booster immunizations.
26 remains high, variant emergence has prompted booster immunizations.
29 ypic marker CD127 and the effectiveness of a booster immunization administered early after the initia
30 low antibody titers to DEN2 and DEN3, but a booster immunization after 4 months increased the neutra
32 ildren and changed post-primary through post-booster immunizations against multiple antigen types, in
33 alized LeTx in vitro 78 days after the final booster immunization and protected the mice from in vivo
34 reached 1:10,000 immediately after the final booster immunization and then decayed to 1:150 at 6 mont
36 various B cell populations, the response to booster immunization, and the generation of plasma cells
37 mmunization with G14D-CCV and at 3 d after a booster immunization as compared with control fish only
39 ustained for at least 7 months following the booster immunization, at which time the secretory IgA an
42 ne regimen used in RV144 have indicated that booster immunizations can increase serum anti-Env antibo
43 moted entry into the brain, but a subsequent booster immunization caused a dramatic accumulation of T
45 amplification of Ag-specific CD8 T cells by booster immunization, despite an undetectable primary re
48 d within 7 days after a single intramuscular booster immunization, even when administered 10-24 years
53 tologous T cells followed by post-transplant booster immunizations improved the severe immunodeficien
62 ondary expansion in response to a variety of booster immunizations, leading to elevated numbers of ef
64 al and cytokine signatures after primary and booster immunizations, MM induced enhanced expression of
71 e they suggest that increasing the number of booster immunizations or delivering additional viral ant
74 immunizations but not when they are used as booster immunizations, suggesting that these APC-modulat
77 to other H5 antigen vaccines, it required a booster immunization to prime protective immune response
78 TM expansion in the presence of TE, enabling booster immunizations to bypass TE-mediated negative fee
79 ed liposome preparations required one or two booster immunizations to develop a substantial anti-AgI/
82 nd whether augmented IgG responses following booster immunization were also dependent on CD4(+) T cel
84 )ICOS(+) cTfh subset clonally expanded after booster immunization whose frequencies correlated with v
85 ons with an E1-deleted Ad vector followed by booster immunization with a poxvirus vector and they sur
86 , but these T cells failed to expand after a booster immunization with a replication-defective adenov
88 IgG2a secretion upon a subsequent intranasal booster immunization with an E1-deleted adenoviral recom
89 es to describe neutralization profiles after booster immunization with bivalent mRNA vaccines based o
91 fied IgG recovered from mice 3 weeks after a booster immunization with live L3 was shown to transfer
92 immune responses were greatly enhanced after booster immunization with recombinant influenza viruses
94 enhance PS-specific IgG responses following booster immunization with their encapsulated isogenic pa
95 V1V2 trimeric scaffold immunogen followed by booster immunizations with a combination of DNA and prot
98 acking the N276 glycan, followed by multiple booster immunizations with glycan-repaired autologous an
99 r of chimpanzee origin allows for sequential booster immunizations with heterologous vaccine carriers
100 ike immune response to GLU after primary and booster immunizations with Salmonella expressing GLU.
101 Ad-SIV immunization, all groups received two booster immunizations with SIV gp140 and SIV Nef protein
103 nst heterologous R5 viruses after one or two booster immunizations with the mismatched oligomeric HIV
104 responses improves only marginally following booster immunizations with the Pfizer-BioNTech or Modern
105 IgA and IgG seroconversion at day 8 1 after booster immunization, with minor changes until day 23 5,
106 o pp65-2 cellular responses after the second booster immunization, with rapid responses observed with
107 ristics, including the ability to respond to booster immunization within days of initial priming.
108 tly, cross-primed CD8 T cells can respond to booster immunization within days of the initial immuniza